-
Solheim Cup on a knife-edge after Korda record
-
Masks banned at planned UK protests: police
-
Corruption probe targets Brazil presidential candidate Flavio Bolsonaro
-
Antonelli on top ahead of Ferraris in Madrid practice
-
New No.1 Rybakina out to thwart Sabalenka US Open three-peat bid
-
Dance Fitness Tempe Announces Expansion of Accessible Digital Movement Programs
-
US marks 25th anniversary of 9/11 attacks
-
Nashville airport to be renamed after Dolly Parton
-
'That's why we fight': Trump links 9/11 to Iran conflict
-
Argentina's Dirty War rears its head in Venice film
-
Europe saw record summer air traffic despite Mideast war: Eurocontrol
-
'Whatever we do is political' says Iranian director Asgari at Venice
-
De Zerbi coy over unsettled Richarlison's Spurs future
-
UK lawmakers throw out bill to legalise assisted dying
-
Brazil president candidate Flavio Bolsonaro targeted in corruption probe
-
Relatives of 9/11 victims hit out at Saudi Arabia -- and US leaders
-
England dismiss Pakistan's Masood to close on victory in 3rd Test
-
Egyptian teenager Abdelkarim to extend Barca deal to 2030
-
Oil prices, US inflation stoke Fed hike worries
-
Macau to hold closed-door trial in first national security case
-
Free-scoring Chelsea must tighten up, says Alonso
-
Philippines recovers 30 bodies from ferry after blaze
-
US inflation steady in August, fueling Fed rate hike expectations
-
Relative of 9/11 victim unleashes searing attack on Saudi Arabia
-
United boss Carrick dismisses Anderson's 'kings of Manchester' jibe
-
Russell edges Antonelli in accident-free opening practice in Madrid
-
New York marks 25th anniversary of 9/11 attacks
-
Sweden's outgoing PM wants to 'make Sweden great again'
-
Yemen's Houthis take over strait vital to global shipping
-
Fenced off: Thailand builds border wall after Cambodia clashes
-
Russia rolls out long-delayed 5G, but not for iPhones
-
Pakistan's Masood frustrates England's victory push in 3rd Test
-
DR Congo Ebola outbreak spreads to 7th province
-
Revitalised Isak in a 'good place' at Liverpool: Iraola
-
Turning up the heat: Arteta reveals 'challenges' for Arsenal stars
-
Arsenal boss Arteta 'very surprised' at Jesus blast over Barcelona move
-
F2 crash in Madrid underlines fears over 'riskiest track'
-
Czech antitrust office lets Turkey's Pegasus Airlines buy Smartwings
-
Nepal flood reconstruction bill to be $4.78 bn: foreign ministry
-
Maresca says spotlight not on him ahead of Manchester derby
-
Investors on edge as energy costs, surging bond yields roil markets
-
Philippine Coast Guard finds bodies aboard ferry after blaze
-
JUMO and Standard Bank launch Social Finance Framework to scale inclusive finance in Africa
-
UK lawmakers to vote again on failed assisted dying bill
-
Doomsday tech: could AI really kill us all?
-
India welcomes Russia, Iran leaders for BRICS summit overshadowed by war
-
Yemen's Houthis complete takeover of Bab al-Mandab area: govt official to AFP
-
Italian feminist fighter Emma Bonino dies
-
Toronto film festival kicks off with ode to political activism
-
White blazers, pink ties as North Koreans land in Japan for Asian Games
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
E.Qaddoumi--SF-PST